Llopiz, Diana
Ruiz, Marta
Villanueva, Lorea
Iglesias, Tamara
Silva, Leyre
Egea, Josune
Lasarte, Juan J. http://orcid.org/0000-0003-1641-3881
Pivette, Perrine
Trochon-Joseph, Véronique
Vasseur, Bérangère
Dixon, Graham
Sangro, Bruno http://orcid.org/0000-0002-4177-6417
Sarobe, Pablo http://orcid.org/0000-0003-0503-7905
Funding for this research was provided by:
Onxeo
Ministerio de Economia y Competitividad/Instituto de Salud Carlos III (PI14/00343, PI17/00249, PI16/01845)
Murchante contra el cáncer
EC Seventh Framework Programme (602893)
Horizon 2020 Framework Programme (AC16/00165)
Fundación Bancaria La Caixa (Hepacare Project)
Article History
Received: 17 January 2018
Accepted: 6 December 2018
First Online: 13 December 2018
Compliance with ethical standards
:
: Perrine Pivette, Véronique Trochon-Joseph, Bérangère Vasseur and Graham Dixon were or are employed by Onxeo. Bruno Sangro received consulting and/or lecture fees from Adaptimmune, Astra Zeneca, Bayer Healthcare, Bristol-Myers-Squibb, Medimmune and Onxeo. All other authors declare that they have no conflict of interest.
: All animal procedures were approved by the Animal Ethics Committee of the Universidad de Navarra (Project approval number: E1-16(149-14E2)). They were in accordance with the ethical standards and guidelines for laboratory animals of the Universidad de Navarra.
: All mice were obtained from Envigo (Barcelona, Spain).
: Hepa129 HCC cells were a kind gift from Dr. M. Gonzalez-Carmona (Bonn, Germany). Re-authentication of cells has not been performed since receipt.
Free to read: This content has been made available to all.